Singapore, May 6 -- US-based AGC Biologics, a global Contract Development and Manufacturing Organisation (CDMO), has announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage biotech company based in South Korea.

Novelty Nobility will leverage AGC Biologics' expertise and proprietary CHEF1 expression technology for cell line development and prepare for Phase I clinical trials via a multi-site partnership with AGC Biologics' Copenhagen, Denmark and Chiba, Japan facilities.

Novelty Nobility develops innovative antibody drugs, including bispecific antibodies and antibody-drug conjugates (ADCs). The company is currently developing two clinical assets in the United States in immunology and oncology, respectively.

AGC B...